Andrew Hsieh receives Bladder Cancer Research Innovation Award

Dr. Andrew Hsieh, professor (Hematology and Oncology) has received a 2025 Bladder Cancer Research Innovation Award from the Bladder Cancer Advocacy Network (BCAN).

These awards support high risk, high reward projects with great potential to produce breakthroughs in our understanding of bladder cancer.

Hsieh’s research aims to uncover how mutations in other commonly altered genes contribute to diversity in bladder cancer. Using advanced methods, his research team will explore how these mutations affect the formation of diverse cell populations and how this impacts tumor growth and response to therapy.

Additionally, Hsieh and the team will test a new drug designed to stop protein production, with the goal of reducing tumor diversity and improving treatment outcomes. By studying how diversity arises and its role in cancer progression, this work could lead to new treatments that target tumor populations, offering hope for patients with advanced and treatment-resistant bladder cancer.

“This award is meaningful because it highlights the importance of our research in bladder cancer heterogeneity and supports the vision of developing methods to target this problem in patients,” he said.